Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422119 | 0.92 | LMNA (0.59) | LMNATP53MAPTESRRGGRM4 | |
| SCHEMBL2415426 | 0.91 | LMNA (0.48) | LMNATP53MAPTESRRGKDM4E | |
| SCHEMBL2417872 | 0.91 | LMNA (0.48) | LMNATP53MAPTNLRP3ESRRG | |
| SCHEMBL2418951 | 0.90 | NR1H4 (0.48) | LMNATP53NLRP3ESRRGGRM4 | |
| SCHEMBL2416650 | 0.89 | MAPT (0.48) | TP53MAPTNLRP3KDM4EPOLB | |
| SCHEMBL2415096 | 0.89 | LMNA (0.46) | LMNATP53NLRP3KDM4EAURKA | |
| SCHEMBL2416783 | 0.87 | TP53 (0.51) | LMNATP53MAPTNLRP3KDM4E | |
| SCHEMBL2415170 | 0.87 | NLRP3 (0.44) | LMNATP53MAPTNLRP3ESRRG | |
| SCHEMBL2419161 | 0.84 | L3MBTL1 (0.53) | TP53MAPTNLRP3POLBMEN1 | |
| SCHEMBL2418266 | 0.84 | TP53 (0.43) | LMNATP53MAPTESRRGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | claimed |
| US-8017643-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-7786048-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-08-31 | — | — | US | disclosed |
| US-20090233813-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2006-06-08 | — | — | US | disclosed |
| EP-1530573-A1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004013146-A1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | CDK2, MAP3K19, MAP3K15 | LMNA 3736/4885P2RX1 2434/4885TP53 282/4885 |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | CDK2, MAP3K19, MAP3K15 | LMNA 3736/4885P2RX1 2434/4885TP53 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.